BioCryst Pharmaceuticals, Inc.
NASDAQBioCryst Pharmaceuticals heads into the post-earnings period with a striking bifurcation: short interest has jumped back toward cycle highs while borrowing costs have crashed to their lowest levels of the year — a combination that paints a picture of conviction on the bear side at bargain-basement terms. The most notable move in short positioning happened between April 23 and April…
BCRX short interest surges 21.5% in one week to 18.1% of float, highest level since late March as cost-to-borrow falls to 0.50%.
Snapshot as of 6 May 2026
BioCryst Pharmaceuticals heads into the post-earnings period with a striking bifurcation: short interest has jumped back toward cycle highs while borrowing costs have crashed to their lowest levels of the year — a…
BioCryst Pharmaceuticals heads into its May 4 Q1 earnings call with short sellers rebuilding positions at pace — and options traders turning more defensive than at any point in recent memory. The week's most striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BCRX — free to start on ORTEX.
Sign up for free →Open BCRX on ORTEX